Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT01080261
Other study ID # S2069
Secondary ID
Status Active, not recruiting
Phase Phase 3
First received March 2, 2010
Last updated August 17, 2012
Start date February 2010
Est. completion date November 2015

Study information

Verified date August 2012
Source Boston Scientific Corporation
Contact n/a
Is FDA regulated No
Health authority Japan: Ministry of Health, Labor and Welfare
Study type Interventional

Clinical Trial Summary

A non-randomized, small vessel (SV) trial at approximately 15 sites in Japan to enroll 60 patients with a de novo lesion ≤28 mm in length (by visual estimate) in a native coronary artery ≥2.25 mm to <2.50 mm in diameter (by visual estimate). Approximately thirty patients will be randomly assigned to the angiographic subset to also undergo angiographic assessment after the 12-month clinical follow-up.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 60
Est. completion date November 2015
Est. primary completion date March 2011
Accepts healthy volunteers No
Gender Both
Age group 20 Years and older
Eligibility Inclusion Criteria:

- Patient must be at least 20 years of age

- Patient understands the study requirements and the treatment procedures and provides written informed consent before any study-specific tests or procedures are performed

- Patient is eligible for percutaneous coronary intervention (PCI) with regards to the target lesion Patient is considered suitable for PCI if any of the following criteria meet.

- Evidence of ischemia documented with stress electrocardiogram (ECG) and/or any diagnostic imaging tests.

- Target vessel supplies blood to relatively large area of the myocardium.

- Target lesion is a possible culprit of angina.

- Target vessel is a potential collateral source for other major vessels

- Patient has documented stable angina pectoris or documented silent ischemia; or unstable angina pectoris

- Patient is an acceptable candidate for coronary artery bypass grafting (CABG)

- Patient has a left ventricular ejection fraction (LVEF) =30% as measured within 30 days prior to enrollment

- Patient is willing to comply with all protocol-required follow-up evaluation

Exclusion Criteria:

- Patient has clinical symptoms and/or ECG changes consistent with acute myocardial infarction (MI)

- Patient has had a known diagnosis of recent MI (i.e., within 72 hours prior to the index procedure) and has elevated enzymes at the time of the index procedure as follows.

- Patients are excluded if any of the following criteria are met at the time of the index procedure.

- If creatine kinase-myoglobin band (CK-MB) is >2× upper limit of normal (ULN), the patient is excluded regardless of the CK Total.

- If CK MB is 1 2× ULN, the patient is excluded if the CK Total is >2× ULN.

- If CK Total/CK MB are not used and Troponin is, patients are excluded if the following criterion is met at the time of the index procedure.

- Troponin >1× ULN with at least one of the following.

- Patient has ischemic symptoms and ECG changes indicative of ongoing ischemia (e.g., >1 mm ST segment elevation or depression in consecutive leads or new left bundle branch block [LBBB]);

- Development of pathological Q waves in the ECG; or

- Imaging evidence of new loss of viable myocardium or new regional wall motion abnormality.

Note: For patients with unstable angina or patients who have had a recent MI, CK Total/CK MB (or Troponin if CK Total/CK MB are not used) must be documented prior to enrolling the patient.

- Patient has received an organ transplant or is on a waiting list for an organ transplant

- Patient is receiving or scheduled to receive chemotherapy within 30 days before or after the index procedure

- Patient is receiving oral or intravenous immunosuppressive therapy (inhaled steroids are not excluded) or has known life-limiting immunosuppressive or autoimmune disease (e.g., human immunodeficiency virus, systemic lupus erythematosus, but not including diabetes mellitus)

- Patient is receiving chronic (=72 hours) anticoagulation therapy (e.g., heparin, warfarin) for indications other than acute coronary syndrome

- Patient has a platelet count <100,000 cells/mm^3 or >700,000 cells/mm^3

- Patient has a white blood cell (WBC) count <3,000 cells/mm^3

- Patient has documented or suspected liver disease, including laboratory evidence of hepatitis

- Patient is on dialysis or has known renal insufficiency (i.e., Creatinine > 2.0 mg/dl or >150 µmol/L)

- Patient has a history of bleeding diathesis or coagulopathy or will refuse blood transfusions

- Patient has had a cerebrovascular accident (CVA) or transient ischemic attack (TIA) within the past 6 months, or has any permanent neurologic defect that may cause non-compliance with the protocol

- Target vessel or side branch has been treated with any type of PCI (e.g., balloon angioplasty, stent, cutting balloon, atherectomy) within 12 months prior to the index procedure (excluding PCI of the non-target lesion within the target vessel treated during the index procedure (Refer to Multiple Interventions During Index Procedure))

- Target vessel has been treated within 10 mm proximal or distal to the target lesion (by visual estimate) with any type of PCI (e.g., balloon angioplasty, stent, cutting balloon, atherectomy) at any time prior to the index procedure

- Non-target vessel or side branch has been treated with any type of PCI (e.g., balloon angioplasty, stent, cutting balloon, atherectomy) within 24 hours prior to the index procedure

- Planned or actual target vessel treatment with an unapproved device, directional or rotational coronary atherectomy, laser, cutting balloon, or transluminal extraction catheter immediately prior to stent placement

- Planned PCI or CABG after the index procedure

- Patient previously treated at any time with coronary intravascular brachytherapy

- Patient has a known allergy to the study stent system or protocol-required concomitant medications (e.g., stainless steel, platinum, chromium, nickel, tungsten, acrylic, fluoropolymers, everolimus, thienopyridines, aspirin, contrast) that cannot be adequately premedicated

- Patient has an active peptic ulcer or active gastrointestinal (GI) bleeding

- Patient has one of the following.

- Other serious medical illness (e.g., cancer, congestive heart failure) that may reduce life expectancy to less than 24 months

- Current problems with substance abuse (e.g., alcohol, cocaine, heroin, etc.)

- Planned procedure that may cause non-compliance with the protocol or confound data interpretation

- Patient is participating in another investigational drug or device clinical trial that has not reached its primary endpoint

- Patient intends to participate in another investigational drug or device clinical trial within 12 months after the index procedure

- Patient with known intention to procreate within 12 months after the index procedure (Women of child-bearing potential who are sexually active must agree to use a reliable method of contraception from the time of screening through 12 months after the index procedure.)

- Patient is a woman who is pregnant or nursing (A pregnancy test must be performed within 7 days prior to the index procedure in women of child-bearing potential.)

- Patient has more than 1 target lesion and 1 non-target lesion, which will be treated during the index procedure

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Intervention

Device:
PROMUS Element
PROMUS Element Everolimus-Eluting Coronary Stent System

Locations

Country Name City State
Japan Hakodate Municipal Hospital Hakodate-shi Hokkaido
Japan Shonan Kamakura General Hospital Kamakura-shi Kanagawa-ken
Japan Japan Labour Health and Welfare Organization Kanto Rosai Hospital Kawasaki-shi Kanagawa-ken
Japan Kokura Memorial Hospital Kitakyushu-shi Fukuoka-ken
Japan Hoshi General Hospital Koriyama-shi Fukushima-ken
Japan Kurashiki Central Hospital Kurashiki-shi Okayama-ken
Japan Kyoto-Katsura Hospital Kyoto-shi Kyoto-fu
Japan Toho University Ohashi Medical Center Meguro-ku Tokyo-tu
Japan The Cardiovascular Institute Hospital Minato-ku Tokyo-to
Japan Hokkaido Social Insurance Hospital Sapporo-shi Hokkaido
Japan Jichi Medical University Hospital Shimotsuke-shi Tochigi-ken
Japan Tokyo Women's Medical University Hospital Shinjuku-ku Tokyo-to
Japan Japan Labour Health and Welfare Organization Kumamoto Rosai Hospital Yatsushiro-shi Kumamoto-ken
Japan Yokohama City University Hospital Yokohama Kanagawa-ken
Japan Saiseikai Yokohama-City Eastern Hospital Yokohama City Kanagawa-ken

Sponsors (1)

Lead Sponsor Collaborator
Boston Scientific Corporation

Country where clinical trial is conducted

Japan, 

Outcome

Type Measure Description Time frame Safety issue
Primary Major Adverse Cardiac Events (MACE) (Percentage of Participants With an Event) A major adverse cardiac event (MACE) is defined as any ischemia-driven target lesion revascularization (TLR), myocardial infarction (MI, Q-wave and non-Q-wave), or cardiac death. Reported as percentage of participants who have experienced a MACE event. 9 months Yes
Secondary Myocardial Infarction (MI) (Percentage of Participants With an Event) New Q-waves in =2 leads lasting =0.04 sec with creatine kinase- myoglobin band (CK-MB) or troponin above upper limit of normal (ULN) (baseline troponin 9 months Yes
Secondary All-cause Death (Percentage of Participants With an Event) Participants who died from any cause 9 months Yes
Secondary Cardiac Death (Percentage of Participants With an Event) Cardiac death is defined as death due to any of the following: acute myocardial infarction; cardiac perforation/pericardial tamponade; arrhythmia or conduction abnormality; cerebrovascular accident (CVA) through hospital discharge or CVA suspected of being related to the procedure; complication of the procedure including bleeding, vascular repair, transfusion reaction, or bypass surgery or any death in which a cardiac cause cannot be excluded. Reported as percentage of participants who experienced cardiac death. 9 months Yes
Secondary Target Vessel Revascularization (Percentage of Participants With an Event) Target vessel revascularization (TVR) is any ischemia-driven repeat percutaneous intervention to improve blood flow, or bypass surgery of not previously existing lesions with diameter stenosis =50% by quantitative coronary angiography in the target vessel, including the target lesion.Reported as percentage of participants who experienced a TVR. 9 months No
Secondary Target Lesion Revascularization (Percentage of Participants With an Event) Target lesion revascularization (TLR) is any ischemia-driven repeat percutaneous intervention, to improve blood flow, of the successfully treated target lesion or bypass surgery of the target vessel with a graft distally to the successfully treated target lesion. Reported as percentage of participants who experienced a TLR. 9 months No
Secondary Target Vessel Failure (TVF) (Percentage of Participants With an Event) Includes any ischemia-driven revascularization of the target vessel, myocardial infarction (MI, Q-wave and non-Q-wave) related to the target vessel or death related to the target vessel. For the purposes of this protocol, if it cannot be determined with certainty whether the MI or death was related to the target vessel, it will be considered a TVF. Reported as percentage of participants who experienced a TVF event. 9 months Yes
Secondary Target Lesion Failure (TLF) (Percentage of Participants With an Event) Target lesion failure (TLF) is defined as any ischemia-driven revascularization of the target lesion, myocardial infarction (Q-wave and non-Q-wave) related to the target vessel, or cardiac death related to the target vessel. Reported as percentage of participants who experienced a TLF event. 9 months Yes
Secondary Definite + Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition (Percentage of Participants With an Event) DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days) 0-30 Days (Early) Yes
Secondary Definite + Probable Stent Thrombosis (ST) Based on Academic Research Consortium (ARC) Definition (Percentage of Participants With an Event) DEFINITE ST: acute coronary syndrome and angiographic or pathologic evidence of stent thrombosis; PROBABLE ST: unexplained death within 30 days or target-vessel infarction without angiographic information ARC ST is reported as a cumulative value at different time points and within the different separate time points. Time 0 is the time point after the guide catheter has been removed. Acute ST: 0-24 hours after stent implantation; Subacute ST: >24 hours to 30 days post; late ST: >30 days to 1 year post; Very late ST: >1 year post; NOTE: Acute/subacute can be replaced by early ST (0-30 days) >30 days - 9 months Yes
Secondary Technical Success (Percentage of Stents) Defined as successful delivery and deployment of the study stent to the target vessel, without balloon rupture or stent embolization; expressed per stent At time of index procedure No
Secondary Clinical Procedural Success (Percentage of Participants) Expressed as percentage of participants in whom mean lesion diameter stenosis was <30% with TIMI 3 flow (visually assessed) and who did not experience an occurrence of in-hospital myocardial infarction, target vessel revascularization, or cardiac death. While participant is in the hospital Yes
See also
  Status Clinical Trial Phase
Recruiting NCT06030596 - SPECT Myocardial Blood Flow Quantification for Diagnosis of Ischemic Heart Disease Determined by Fraction Flow Reserve
Completed NCT04080700 - Korean Prospective Registry for Evaluating the Safety and Efficacy of Distal Radial Approach (KODRA)
Recruiting NCT03810599 - Patient-reported Outcomes in the Bergen Early Cardiac Rehabilitation Study N/A
Recruiting NCT06002932 - Comparison of PROVISIONal 1-stent Strategy With DEB Versus Planned 2-stent Strategy in Coronary Bifurcation Lesions. N/A
Not yet recruiting NCT06032572 - Evaluation of the Safety and Effectiveness of the VRS100 System in PCI (ESSENCE) N/A
Recruiting NCT05308719 - Nasal Oxygen Therapy After Cardiac Surgery N/A
Recruiting NCT04242134 - Drug-coating Balloon Angioplasties for True Coronary Bifurcation Lesions N/A
Completed NCT04556994 - Phase 1 Cardiac Rehabilitation With and Without Lower Limb Paddling Effects in Post CABG Patients. N/A
Recruiting NCT05846893 - Drug-Coated Balloon vs. Drug-Eluting Stent for Clinical Outcomes in Patients With Large Coronary Artery Disease N/A
Recruiting NCT06027788 - CTSN Embolic Protection Trial N/A
Recruiting NCT05023629 - STunning After Balloon Occlusion N/A
Completed NCT04941560 - Assessing the Association Between Multi-dimension Facial Characteristics and Coronary Artery Diseases
Completed NCT04006288 - Switching From DAPT to Dual Pathway Inhibition With Low-dose Rivaroxaban in Adjunct to Aspirin in Patients With Coronary Artery Disease Phase 4
Completed NCT01860274 - Meshed Vein Graft Patency Trial - VEST N/A
Recruiting NCT06174090 - The Effect of Video Education on Pain, Anxiety and Knowledge Levels of Coronary Bypass Graft Surgery Patients N/A
Terminated NCT03959072 - Cardiac Cath Lab Staff Radiation Exposure
Completed NCT03968809 - Role of Cardioflux in Predicting Coronary Artery Disease (CAD) Outcomes
Recruiting NCT05065073 - Iso-Osmolar vs. Low-Osmolar Contrast Agents for Optical Coherence Tomography Phase 4
Recruiting NCT04566497 - Assessment of Adverse Outcome in Asymptomatic Patients With Prior Coronary Revascularization Who Have a Systematic Stress Testing Strategy Or a Non-testing Strategy During Long-term Follow-up. N/A
Completed NCT05096442 - Compare the Safety and Efficacy of Genoss® DCB and SeQuent® Please NEO in Korean Patients With Coronary De Novo Lesions N/A